• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Cannabis

Covid-19 Is Not Hurting the Cannabis Industry

Still, Covid has forced attention on company balance sheets and a hard look at cash burn rates and investment choices.
By DEBRA BORCHARDT
May 14, 2020 | 01:00 PM EDT
Stocks quotes in this article: CRLBF, AYRSF, CWBHF, GTBIF, MEDIF, OGI

Canaccord Genuity held its fourth annual cannabis conference this week, but like other events, this one went virtual. The company reported that it had close to 800 participants and 250 institutional investors. Canaccord also released a report on May 13 recapping the top themes and highlighting several companies.

Covid-19

Canaccord highlighted some of the key themes that were discussed at the conference. Luckily, Covid-19 has not been as bad for cannabis as it has been for other industries. Supply chains appear to be uninterrupted due to cannabis being named an essential service. Social distancing measure and stay-at-home directives did cause many operators to experience a spike in demand in March as consumers stocked up.

Many companies actually found a silver lining in the virus cloud as many were forced to focus on various parts of their operations in order to identify areas that could be improved for efficiency. Cost control efforts could be blamed on Covid and companies would not receive any negative blowback. Still, Covid has forced attention on company balance sheets and a hard look at cash burn rates and investment choices.

Execution

2019 was all about expansion and planting flags in as many states as possible, but 2020 is all about execution and delivering on message. More attention is being paid to realistic pathways to profitability and capital allocation. 2019 was notable for the race to have the most licenses, while 2020 has shifted to being a leader in a smaller number of markets. For example, while many companies were racing to get into California because of the size of the market, Cresco Labs (CRLBF) and GTI looked like winners for going after Illinois instead. Illinois has turned out to be a huge state for sales, with fewer of the headaches of the California market and less competition.

Forecast

Canaccord believes the cannabis industry has the potential to reach upwards of $100 billion in annual revenues over the next decade. The analysts also believe that in 2020, despite most of the markets only being medical, revenues could hit $18 billion.

Company Highlights

Canaccord rarely says anything negative about the cannabis companies as it acts as a banker for many of them. Instead, words like challenges and headwinds feature into narrative. Companies that are known to be struggling continue to receive speculative buy ratings. Having said that, here are some of the key highlights from Canaccord's industry note dated May 13.

AYR Strategies (AYRSF)  

"Given the company's cash position and positive cash flows forecasted for this year despite headwinds, we continue to believe AYR is one of the best positioned companies in the space to weather prolonged market headwinds. Additionally, as other operators in the space face capital challenges, we believe AYR will be positioned to complete strategic acquisitions at attractive multiples."

Charlotte's Web Holdings (CWBHF)

On May 14, Charlotte's Web Holdings, Inc. reported slipping first-quarter revenue for the quarter ending March 31, 2020. The company delivered revenue of $21.5 million, slightly below last year's revenue of $21.7 million for the same time period in 2019. However, this beat the Yahoo! Finance average analyst estimate of $20.78 million. Canaccord wrote, "The company continues to be the market leader, with over 35% market share following the announcement of the acquisition of Abacus. Innovation remains a key pillar of growth for Charlotte s Web, with the company having introduced new product form factors, an extended line-up of topical products, and increased canine products over recent months. we believe Charlotte s Web is well positioned to continue its market dominance, given its leading brand awareness, vertically integrated infrastructure, and healthy balance sheet, as the market for CBD products continues to grow."

Cresco Labs (CRLBF)  

"The company recently completed construction and expansion at two of its Illinois cultivation facilities, leaving the company well positioned to capture market share and remain a leader within the high growth, but currently undersupplied Illinois market. Meanwhile, Pennsylvania remains one of the most attractive medical markets in the US, with Cresco recently doubling its cultivation capacity within the state, which should allow the company to maintain its 25%+ market share within Pennsylvania. Furthermore, recent sale-leaseback activity, coupled with the addition of a $100M term loan, positions Cresco with one of the industry s best balance sheets. This, in our view, will help support growth initiatives throughout 2020, and cement the company s status as a market leader."

Green Thumb Industries (GTBIF)

"In 2019, the company reported annual revenues of >US$216M. GTI will be reporting its FQ1/20 financial results after market on Thursday, May 14, 2020, which will, for the first time, include an entire quarter s contribution from the recently legalized Illinois adult-use market. In the first quarter of 2020, Illinois saw ~US$110M in total adult-use sales where we believe GTI is competing with CL for the top spot in this newly opened market."

MediPharm Labs (MEDIF)

"MediPharm has plans to launch additional CBD formulations in the near term, along with some THC blends and topical formulations thereafter, while Ace Valley-branded products are set to be launched by month end. The company continues to explore novel cannabinoids such as CBN as a sleep aid and THCV as an appetite suppressant; however, a significant hurdle to commercialization is determining and procuring the best genetics to maximize cannabinoid yields.

OrganiGram Holdings (OGI)

"OGI recently began selling its value-focused brand, Trailer Park Boys, which Mr. Engel s stated as being very well-received since its launch. He went on to further detail the company s strategy around the cannabis 2.0 market, citing that the company prioritized completing construction of it vape and chocolates infrastructure, and, as a result, these segments contributed 15% of revenues in its most recent quarter."

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Debra Borchardt had no position in the securities mentioned.

TAGS: Earnings | Economy | Investing | Markets | Stocks | Trading | Canada | Analyst Actions | Cannabis | Coronavirus

More from Cannabis

As the Market Struggles to Bounce Back, Here's My Game Plan

James "Rev Shark" DePorre
May 12, 2022 11:04 AM EDT

Many stocks are very oversold, and sentiment is about as bad as it gets.

A New Pot ETF Just Lit Up, So Let's Get Deep Into the WEEDs

Mark Abssy
Apr 21, 2022 1:35 PM EDT

Here we'll hash out the differences among cannabis players and see high how Roundhill Investment's The Cannabis ETF can go.

Mosaic's Chart Pattern Suggests Its Share Price Could Grow Even Bigger

Ed Ponsi
Apr 8, 2022 10:00 AM EDT

Pressure on fertilizer supplies due to sanctions against Russia because of the war in Ukraine makes the potash producer a star performer in a down market.

I Wouldn't Go 'All In' on Tilray, But Here's How I'd Trade It

Stephen Guilfoyle
Apr 6, 2022 10:50 AM EDT

Tilray is okay in my book for speculation.

Watching for an Upside Move in Cannabis Names

James "Rev Shark" DePorre
Mar 25, 2022 1:20 PM EDT

There should be some better trading action and setups as things pull back.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A new, very scary movie

  • 08:51 AM EDT PAUL PRICE

    Advice from the future...

  • 12:20 PM EDT PAUL PRICE

    A blast from the past regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login